Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

We are currently developing three product candidates under our INOpulse pro... more >

more >

Recent News

01/28/19

Summary Toggle Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients

Actigraphy is Being Utilized to Evaluate Multiple Clinically Meaningful Activity Parameters in the Ongoing INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease Data to be Presented in a Poster Session at the 13 th Annual Pulmonary
01/25/19

Summary Toggle Bellerophon Announces Closing of $7 Million Public Offering of Common Stock

WARREN, N.J. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the closing and funding of its previously announced underwritten public offering of 10,000,000 shares of its
01/23/19

Summary Toggle Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock

WARREN, N.J. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering

more >

Stock Quote

more >

Bellerophon (: )

Data as of 02/22/19 8:04 AM EST

more >

Presentations

Corporate Presentation

01/07/19

Corporate Presentation 2.2 MB
Key Opinion Leader Lunch : Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) with Dr. Steve Nathan

08/09/17

Key Opinion Leader Lunch : Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) with Dr. Steve Nathan 4.5 MB
2017 ATS Poster - PH-IPF

05/23/17

2017 ATS Poster - PH-IPF 2.2 MB
2017 ATS Poster - PH-COPD

05/23/17

2017 ATS Poster - PH-COPD 3 MB
2017 ISHLT Poster

04/06/17

2017 ISHLT Poster 417.9 KB
2016 ATS Poster

05/19/16

2016 ATS Poster 971 KB
2015 PHPN Poster

09/19/15

2015 PHPN Poster 684.5 KB

Investors

Corporate Profile

Recent News

Stock Quote

Upcoming Events

Presentations

Corporate Presentation

Key Opinion Leader Lunch : Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) with Dr. Steve Nathan

2017 ATS Poster - PH-IPF

2017 ATS Poster - PH-COPD

2017 ISHLT Poster

2016 ATS Poster

2015 PHPN Poster